A new method to measure the formation of amyloid-beta proteins linked to Alzheimer's disease
Official title: A high-throughput assay to measure amyloid-β oligomer formation
Funded at University of Wisconsin-Madison · NIH-10947549 · Data updated 2026-11-12
This study is looking at how certain proteins related to Alzheimer's disease clump together, and it aims to create a new way to quickly test different factors that might help us find better treatments for the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | September 15, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $219,930 |
| NIH project number | 1R21AG088715-01 |
| Project ID | NIH-10947549 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those with early signs of cognitive decline.
✕Less likely to help
Patients with other forms of dementia unrelated to amyloid-beta pathology may not benefit from this research.
What this research studies
This research focuses on understanding how toxic amyloid-beta (Aβ) proteins form oligomers, which are believed to play a significant role in Alzheimer's disease. The team will develop a novel high-throughput assay using a genetically encoded sensor that detects Aβ oligomer formation and translates this into measurable signals. This innovative approach allows for the rapid testing of various factors that may influence oligomerization, potentially leading to the identification of new therapeutic agents. By improving our understanding of Aβ oligomers, the research aims to contribute to the development of effective treatments for Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating Alzheimer's disease by targeting the formation of harmful amyloid-beta oligomers.
How similar studies have gone: Previous research has shown promise in understanding amyloid-beta oligomerization, but this high-throughput approach represents a novel method that has not been extensively tested.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Wang, Tina — University of Wisconsin-Madison
- Study coordinator: Wang, Tina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.